JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
Read original at benzingaStocks · News reference
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Read original at benzingaTruist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39
Read original at benzingaHC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55
Read original at benzingaWedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Read original at benzingaBMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Read original at benzinga